|
|
|
|
| LEADER |
03914nmm a2200289 u 4500 |
| 001 |
EB001651972 |
| 003 |
EBX01000000000000000954647 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
171103 ||| eng |
| 020 |
|
|
|a 9789811044663
|
| 100 |
1 |
|
|a Hanaoka, Masayuki
|e [editor]
|
| 245 |
0 |
0 |
|a Drug-Induced Lung Injury
|h Elektronische Ressource
|c edited by Masayuki Hanaoka, Hiroyuki Nakamura, Kazutetsu Aoshiba
|
| 250 |
|
|
|a 1st ed. 2018
|
| 260 |
|
|
|a Singapore
|b Springer Nature Singapore
|c 2018, 2018
|
| 300 |
|
|
|a VIII, 215 p. 53 illus., 15 illus. in color
|b online resource
|
| 505 |
0 |
|
|a Part I Definition, Pathogenesis, and Epidemiology -- 1. Definition, Pathogenesis and Epidemiology: What is DLI? -- 2. Epidemiology and Risk Factors of Drug-Induced Lung Disease: What are the prevalence and risk factors of DLI? -- 3. Clinical Characteristics of DLI: What are the clinical features of DLI? -- Part II Diagnosis -- 4. Diagnostic Approach for DLI: How is DLI diagnosed? -- 5. Blood tests for the diagnosis and/or management of DLI: What are the clinical significances of KL-6, SP-A, SP-D and DLST in DLI? -- 6. Imaging features of drug-induced interstitial lung disease: How HRCT of DLI is interpreted? -- 7. Pathology of DLI: What is the pathological significance of DLI? -- 8. Differential Diagnosis of DLI: What are the differential diagnoses of DLI? -- Part II Treatment -- 9. Therapeutic Strategies for DLI: How should DLI be treated? -- Part IV Drugs Causing DLI -- 10. DLI induced by non-molecular target antineoplastic drugs: What are the characteristics of DLI in non-molecular target antineoplastic drugs? -- 11. DLI induced by Molecular Target Antineoplastic Drug: What are the characteristics of DLI in molecular target antineo-plastic drugs? -- 12. DLI caused by disease-modifying antirheumatic drugs: What are the characteristics of DLI by disease-modifying antirheumatic drugs? -- 13. DLI Induced by Herbal Medicine: What are the characteristics of DLI due to herbal medicines? -- 14. DLI induced by Antiarrhythmic Drug and Antimicrobial Drug: What are the characteristics of DLI in antiarrhythmic drugs and antimicrobial drugs?
|
| 653 |
|
|
|a Pneumology
|
| 653 |
|
|
|a Respiratory organs—Diseases
|
| 700 |
1 |
|
|a Nakamura, Hiroyuki
|e [editor]
|
| 700 |
1 |
|
|a Aoshiba, Kazutetsu
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a Respiratory Disease Series: Diagnostic Tools and Disease Managements
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-981-10-4466-3?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.2
|
| 520 |
|
|
|a This book covers various aspects of a respiratory system disorder associated with prescribed drugs that do not yet have established treatment guidelines, and for which the only treatment is to discontinue taking the drug. Very little clinical evidence regarding the disorder is available, since randomized trials cannot to be carried out, the onset of the disorder cannot be predicted, and the resulting pathological condition is life-threatening. However, the need for an established treatment continues to grow due to the introduction of many new drugs, such as anti-neoplastic drugs, biological products, and molecular target drugs, the adverse effects of which are difficult to differentiate from those of other lung diseases, such as lung infectious diseases. Drug-Induced Lung Injury offers a highly beneficial resource not only for respiratory physicians but also all medical clinicians who prescribe drugs, nurses, pharmacists and pharmaceutical scientists. Written by pioneering experts in the field, the book examines a wealth of cases and the insights they yield concerning the diagnosis, treatment and specific drugs causing the disease. It not only fosters a deeper understanding of the disorder but also highlights the current challenges and paves the way for future clinical research
|